Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment
Stopped This study is prematurely terminated due to changes in sponsor's overall development strategy. The decision of termination is not related to any safety concern of the compound.
Conditions
Interventions
- DRUG: Runcaciguat (BAY1101042)
Sponsor
Bayer